GLP1R and metabolic dysfunction-associated steatohepatitis: Efocipegtrutide, a long-acting GLP-1/glucagon/gastric inhibitory polypeptide triple agonist, has shown promising efficacy and controllable toxicity in preclinical and Phase 1 studies for NASH.